NanoBio Corporation and GlaxoSmithKline Commence Phase 3 Studies of Nanoemulsion-based OTC Treatment for Cold Sores

May 11, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NanoBio® Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare (GSK CH).

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 3

GSK